Clinical trials: Lung Cancer Small Cell Lung Cancer (SCLC)
Non-Small-Cell Lung Cancer
A Study of SBRT Combined With Puterizumab in Intrapulmonary Metastasis From NSCLC
This study aims to evaluate the efficacy and safety of SBRT combined with Puterizumab immunotherapy for non-small cell lung cancer with pulmonary metastases, and to determine the correlation between MRD and treatment efficacy.
- Trial name
- NCT06434740
- Testing
- Stereotactic Body Radiation Therapy，SBRT, Puterizumab
- Volunteers
- 37 people
- Sponsor
- Sir Run Run Shaw Hospital
Lung Cancer
Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor…
- Trial name
- NCT00287989
- Testing
- Carboplatin, erlotinib hydrochloride, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 86 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Neoplasms,, Metastatic Cancer,
Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer
The objective of this study will be to investigate the safety and tolerability of AZD6244 given monotherapy or in combination with docetaxel as 2nd line therapy in Japanese patients with Advanced Solid Malignancies or Locally…
- Conditions
- Neoplasms,, Metastatic Cancer,, Non-Small Cell Lung Cancer, Advanced Solid Malignancies
- Trial name
- NCT01605916
- Testing
- AZD6244
- Where
- 3 sites in Japan
- Volunteers
- 33 people
- Sponsor
- AstraZeneca
Lung Cancer
Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma
Both pemetrexed and erlotinib are second-line treatment options for patients with advanced non-small cell lung cancer. It is controversial that whether it is necessary to detect epidermal growth factor receptor (EGFR) mutation…
- Trial name
- NCT01565538
- Testing
- Erlotinib, Pemetrexed
- Where
- China
- Volunteers
- 123 people
- Sponsor
- Si-Yu Wang
Small Cell Lung Cancer
Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects
This study is a single arm, multi-center phase II study of durvalumab and AZD6738 combination therapy in subjects with relapsed small cell lung cancer (SCLC) as a second or third line chemotherapy.
- Trial name
- SUKSES-N4 (NCT04361825)
- Testing
- Durvalumab
- Where
- 2 sites in South Korea
- Volunteers
- 42 people
- Sponsor
- Se-Hoon Lee
Nonsmall Cell Lung Cancer
Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer
Based on the efficacy of immunotherapies in advanced disease with a reasonable safety profile/tolerability we could hypothesize that, immunotherapy should work best in the situation of minimal residual disease, Two clinical…
- Trial name
- PRINCEPS (NCT02994576)
- Testing
- Atezolizumab
- Where
- 3 sites in France
- Volunteers
- 60 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Non Small Cell Lung Carcinoma
Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to determine if TLK286(Telcyta) is more effective than gefitinib (Iressa) in the treatment of non-small cell lung cancer.
- Trial name
- NCT00080340
- Testing
- TLK286 (Telcyta) HCl for Injection, gefitinib (Iressa)
- Where
- 338 sites in United States, Argentina and 6 more
- Volunteers
- 520 people
- Sponsor
- Telik
Lung Cancer, Adenocarcinoma of the Lung
Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung
The purpose of this study is to find out what effects (good and bad) a tumor vaccine (GM.CD40L) used in combination with Nivolumab will have on participants and their cancer.
- Trial name
- NCT02466568
- Testing
- Nivolumab, GM.CD40L Vaccine
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Neoplasms
A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent
N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin.
- Trial name
- NCT00264433
- Testing
- ADH -1 (Exherin™)
- Where
- 11 sites in United States, Canada
- Sponsor
- Adherex Technologies, Inc.
Non-small Cell Lung Cancer
A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients
This study is designed to evaluate the untreated NSCLC patients. After participants have accepted chemotherapy, radiotherapy, and immunotherapy, the investigators used the next generation sequence technology (NGS) to construct…
- Trial name
- NCT03373955
- Testing
- pembrolizumab
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sichuan University
Lung Cancer
Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
This is a Phase 1b pre-operative lung cancer trial wherein patients with operable lung cancer will be treated with RAD001 to evaluate the target effects of this compounds on relevant molecular pathways and on the…
- Trial name
- NCT00401778
- Testing
- RAD001
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Emory University
Minimal Residual Disease, KRAS G12D
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides])…
- Conditions
- Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D
- Trial name
- AMPLIFY-201 (NCT04853017)
- Testing
- ELI-002 2P
- Where
- 10 sites in United States
- Volunteers
- 25 people
- Sponsor
- Elicio Therapeutics
Non Small Cell Lung Cancer
Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLC
This is a single-arm phase II trial to evaluate the efficacy and safety of atezolizumab and bevacizumab combination therapy (stage 2) after radiologic progression of atezolizumab monotherapy (stage 1) in Korean patients with…
- Trial name
- NCT03616691
- Testing
- Atezolizumab, Bevacizumab
- Volunteers
- 46 people
- Sponsor
- Samsung Medical Center
Small Cell Lung Carcinoma
Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain
This phase I/II trial studies the effects and safety of giving lithium carbonate (lithium) to patients with small cell lung cancer (SCLC) undergoing radiation therapy to the brain (PCI; prophylactic cranial irradiation).
- Trial name
- NCT01553916
- Testing
- Lithium Carbonate, Prophylactic cranial irradiation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Washington University School of Medicine
Non-Squamous Non-Small Cell Lung Cancer
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to evaluate whether telisotuzumab adizutecan improves response rate and…
- Trial name
- NCT07821684
- Testing
- Telisotuzumab Adizutecan, Docetaxel, Ramucirumab
- Volunteers
- 660 people
- Sponsor
- AbbVie
Non-small Cell Lung Cancer
The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer
This study was a multicenter, real-world observational study aimed at characterizing the genomic landscape of recurrence in patients with EGFR-sensitizing mutation-positive early-stage (clinical stage IB-IIIA) non-small cell lung…
- Trial name
- RAISE (NCT06477055)
- Where
- 2 sites in China
- Volunteers
- 43 people
- Sponsor
- Hunan Province Tumor Hospital
EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine
Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors
Background: Lung cancers with epidermal growth factor receptor (EGFR) mutations may develop resistance to therapies targeting this protein by evolving/being transformed into small cell or neuroendocrine cancers.
- Trial name
- NCT04538378
- Testing
- Olaparib, Durvalumab, EKG
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung
Efficacy Study of Additional Chemotherapy After Concurrent Chemoradiation in Non-small Cell Lung Cancer
Non-Small Cell Lung Cancer(NSCLC) is the leading cause of death in Korean men after stomach cancer. Surgical resection plays a main role for curative treatment.
- Trial name
- NCT00326378
- Testing
- consolidation chemotherapy with Docetaxel plus cisplatin, CCRT arm without consolidation chemotherapy
- Where
- South Korea
- Volunteers
- 434 people
- Sponsor
- Samsung Medical Center
Non-Small Cell Lung Cancer
Anlotinib Single Drug as the Maintenance Treatment for Advanced NSCLC
Based on the need of clinical practice of maintenance therapy for advanced NSCLC and the reliable data of third-line treatment for non-small cell lung cancer, the investigators designed a clinical study of anlotinib in…
- Trial name
- NCT03998085
- Testing
- Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Hospital of Jilin University
Carcinoma, Non-Small-Cell Lung
Predictive Assay for Decision Making in Adjuvant Therapy
Prospective Registrational Trial to Define Real World Outcomes of Patients with Completely Resected Stage I or IIA (tumor < or = 5cm, node negative) Non-squamous Non-Small Lung Cancer (NSCLC) Identified as High, Intermediate, or…
- Trial name
- PADMA (NCT05032352)
- Testing
- Adjuvant, Observation
- Where
- 18 sites in United States
- Volunteers
- 55 people
- Sponsor
- Insight Molecular Diagnostics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.